Cetuximab News and Research

RSS
Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.
Patients with advanced colorectal cancer respond well to new combination therapy

Patients with advanced colorectal cancer respond well to new combination therapy

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

Study: Cetuximab drug used in combination with chemotherapy to treat advanced colorectal cancer is not effective

Study: Cetuximab drug used in combination with chemotherapy to treat advanced colorectal cancer is not effective

Scientist receives $275,000 grant to study human papillomavirus that causes head and neck cancer

Scientist receives $275,000 grant to study human papillomavirus that causes head and neck cancer

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Study: Recurrence of SCCOP may differ in HPV-positive and HPV-negative patients

Study: Recurrence of SCCOP may differ in HPV-positive and HPV-negative patients

HPV-positive patients with OPSCC show higher overall survival rate than HPV-negative patients

HPV-positive patients with OPSCC show higher overall survival rate than HPV-negative patients

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Tumor profiling study of colorectal cancer to be presented at 2014 Gastrointestinal Cancers Symposium

Tumor profiling study of colorectal cancer to be presented at 2014 Gastrointestinal Cancers Symposium

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

European Commission approves update of Erbitux  to treat patients with RAS wild-type mCRC

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Cetuximab fails in second-line combination for recurrent NSCLC

Cetuximab fails in second-line combination for recurrent NSCLC

Four-drug regimen shows first-line efficacy in advanced NSCLC

Four-drug regimen shows first-line efficacy in advanced NSCLC

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Lung cancer patients who received IMRT report less decline in their QOL

Lung cancer patients who received IMRT report less decline in their QOL

Human tumors with MET amplification respond to MET inhibitor drugs

Human tumors with MET amplification respond to MET inhibitor drugs

New clinical trial may help reduce radiation dose for patients with HPV-positive oropharyngeal cancer

New clinical trial may help reduce radiation dose for patients with HPV-positive oropharyngeal cancer